FEDERAL TRADE COMMISSION v. ABBVIE INC et al

  1. July 30, 2021

    FTC Drops AndroGel Antitrust Case Against AbbVie

    The Federal Trade Commission is dropping its long-running case accusing AbbVie of illegally delaying generic versions of the testosterone treatment AndroGel, saying Friday the case shows enforcers need new legislation to help them recover money for consumers.

  2. October 29, 2019

    ​​​​​​​Allergan's $750M Deal Among Pharma's Top Antitrust Payouts

    A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.

  3. February 20, 2019

    FTC's Teva Settlement A Sign Of Enforcement Evolution

    The Federal Trade Commission's settlement this week with Teva Pharmaceuticals further winnows the types of deals the company can sign with would-be competitors and illuminates the agency's evolving approach to cases in which drug companies are accused of colluding to delay competition.

  4. February 19, 2019

    FTC Pens New Deal With Teva On Reverse-Payment Claims

    The Federal Trade Commission said Tuesday it has reached an agreement with Teva Pharmaceuticals that would prevent the drugmaker from entering into certain reverse-payment patent settlements that can delay the availability of generic versions of drugs.

  5. July 23, 2018

    FTC To Seek Revival Of Parts Of AbbVie Suit After $448M Win

    The Federal Trade Commission said in Pennsylvania federal court that it will be asking the Third Circuit to revive nixed parts of an antitrust lawsuit against AbbVie Inc. and its partner even after the agency won a $448 million penalty against the drugmakers, plus interest, over alleged sham AndroGel patent lawsuits.

  6. July 19, 2018

    AbbVie Judge Rejects Interest Hike On AndroGel Penalty

    AbbVie Inc. got a partial win in Pennsylvania federal court on Wednesday when a judge rejected a nearly 57 percent interest hike that the Federal Trade Commission proposed for the drugmaker's $448 million penalty over alleged sham AndroGel patent lawsuits.

  7. July 16, 2018

    AbbVie Protests FTC Interest Hike In AndroGel Case

    AbbVie Inc. has accused the Federal Trade Commission of suddenly hiking the interest rate it and an affiliate must pay on a $448 million penalty over sham patent suits that delayed generic drug rollouts and extended their monopoly on AndroGel.

  8. June 29, 2018

    AbbVie, Besins Owe $448M In FTC Androgel Antitrust Case

    AbbVie Inc. and an affiliate must pay $448 million in the Federal Trade Commission's suit alleging they netted more than $1 billion after bringing sham patent lawsuits to stave off generic competition to AbbVie's AndroGel testosterone replacement drug, a Pennsylvania federal court ruled Friday.

  9. February 07, 2018

    AbbVie Filed Patent Suits To Delay Competition, Court Told

    The patent lawsuits filed by AbbVie Inc. and Besins Healthcare Inc. over generic testosterone replacement treatments were "anti-competitive weapons" used to delay competition for the brand-name drug AndroGel, an attorney for the Federal Trade Commission said Wednesday while opening the bench trial in the agency's antitrust suit in Pennsylvania federal court.

  10. September 15, 2017

    AbbVie AndroGel Patent Suits Baseless, Pa. Judge Finds

    A Pennsylvania federal judge on Friday granted a partial victory to the Federal Trade Commission in its lawsuit alleging drugmakers including AbbVie Inc. filed sham patent litigation against generic rivals over AbbVie's testosterone replacement treatment AndroGel, finding the suits to be without merit based on the patent's prosecution history.